These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 36725090)
1. Personalised azithromycin+metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn's disease (CD): protocol of a pilot study. Verburgt CM; Dunn KA; Otley A; Heyman MB; Verstraete S; Sunseri W; Sylvester F; de Meij T; Comeau A; Langille M; de Jonge WJ; Benninga MA; Van Limbergen JE BMJ Open; 2023 Feb; 13(2):e064944. PubMed ID: 36725090 [TBL] [Abstract][Full Text] [Related]
2. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial. Levine A; Kori M; Kierkus J; Sigall Boneh R; Sladek M; Escher JC; Wine E; Yerushalmi B; Amil Dias J; Shaoul R; Veereman Wauters G; Boaz M; Abitbol G; Bousvaros A; Turner D Gut; 2019 Feb; 68(2):239-247. PubMed ID: 29420227 [TBL] [Abstract][Full Text] [Related]
3. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. Yanai H; Levine A; Hirsch A; Boneh RS; Kopylov U; Eran HB; Cohen NA; Ron Y; Goren I; Leibovitzh H; Wardi J; Zittan E; Ziv-Baran T; Abramas L; Fliss-Isakov N; Raykhel B; Gik TP; Dotan I; Maharshak N Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):49-59. PubMed ID: 34739863 [TBL] [Abstract][Full Text] [Related]
4. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Levine A; Wine E; Assa A; Sigall Boneh R; Shaoul R; Kori M; Cohen S; Peleg S; Shamaly H; On A; Millman P; Abramas L; Ziv-Baran T; Grant S; Abitbol G; Dunn KA; Bielawski JP; Van Limbergen J Gastroenterology; 2019 Aug; 157(2):440-450.e8. PubMed ID: 31170412 [TBL] [Abstract][Full Text] [Related]
5. Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn's Disease Cohort. Sprockett D; Fischer N; Boneh RS; Turner D; Kierkus J; Sladek M; Escher JC; Wine E; Yerushalmi B; Dias JA; Shaoul R; Kori M; Snapper SB; Holmes S; Bousvaros A; Levine A; Relman DA Inflamm Bowel Dis; 2019 Nov; 25(12):1927-1938. PubMed ID: 31276165 [TBL] [Abstract][Full Text] [Related]
6. Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA. Minar PP; Colman RJ; Zhang N; Mizuno T; Vinks AA BMJ Open; 2024 Mar; 14(3):e077193. PubMed ID: 38531570 [TBL] [Abstract][Full Text] [Related]
7. Formula modifications to the Crohn's disease exclusion diet do not impact therapy success in paediatric Crohn's disease. Landorf E; Hammond P; Abu-Assi R; Ellison S; Boyle T; Comerford A; Couper R J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1279-1286. PubMed ID: 38623960 [TBL] [Abstract][Full Text] [Related]
8. The effect of solid food diet therapies on the induction and maintenance of remission in Crohn's disease: a systematic review. Zhang JL; Vootukuru N; Niewiadomski O BMC Gastroenterol; 2024 Aug; 24(1):250. PubMed ID: 39107691 [TBL] [Abstract][Full Text] [Related]
9. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease. Levine A; Turner D J Crohns Colitis; 2011 Jun; 5(3):222-6. PubMed ID: 21575885 [TBL] [Abstract][Full Text] [Related]
10. Protocol for a double-blind, randomised, placebo-controlled pilot study for assessing the feasibility and efficacy of faecal microbiota transplant in a paediatric Crohn's disease population: PediCRaFT Trial. Pai N; Popov J; Hill L; Hartung E BMJ Open; 2019 Nov; 9(11):e030120. PubMed ID: 31784432 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Crohn's disease exclusion diet in treatment -naïve children and children progressed on biological therapy: a retrospective chart review. Jijón Andrade MC; Pujol Muncunill G; Lozano Ruf A; Álvarez Carnero L; Vila Miravet V; García Arenas D; Egea Castillo N; Martín de Carpi J BMC Gastroenterol; 2023 Jun; 23(1):225. PubMed ID: 37386458 [TBL] [Abstract][Full Text] [Related]
12. Antibiotics for induction and maintenance of remission in Crohn's disease. Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030 [TBL] [Abstract][Full Text] [Related]
13. Treatment of Active Crohn's Disease in Children Using Partial Enteral Nutrition Combined with a Modified Crohn's Disease Exclusion Diet: A Pilot Prospective Cohort Trial on Clinical and Endoscopic Outcomes. Urlep D; Orel R; Kunstek P; Benedik E Nutrients; 2023 Nov; 15(21):. PubMed ID: 37960328 [TBL] [Abstract][Full Text] [Related]
14. Sustained Diet-Induced Remission in Pediatric Crohn's Disease Is Associated With Kynurenine and Serotonin Pathways. Ghiboub M; Boneh RS; Sovran B; Wine E; Lefèvre A; Emond P; Verburgt CM; Benninga MA; de Jonge WJ; Van Limbergen JE Inflamm Bowel Dis; 2023 May; 29(5):684-694. PubMed ID: 36637175 [TBL] [Abstract][Full Text] [Related]
15. Effect of the Crohn's Disease Exclusion Diet (CDED) on the Fecal Calprotectin Level in Children with Active Crohn's Disease. Matuszczyk M; Meglicka M; Wiernicka A; Jarzębicka D; Osiecki M; Kotkowicz-Szczur M; Kierkuś J J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887910 [TBL] [Abstract][Full Text] [Related]
16. Metabolome Changes With Diet-Induced Remission in Pediatric Crohn's Disease. Ghiboub M; Penny S; Verburgt CM; Boneh RS; Wine E; Cohen A; Dunn KA; Pinto DM; Benninga MA; de Jonge WJ; Levine A; Van Limbergen JE Gastroenterology; 2022 Oct; 163(4):922-936.e15. PubMed ID: 35679949 [TBL] [Abstract][Full Text] [Related]
17. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course. Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK; BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737 [TBL] [Abstract][Full Text] [Related]
18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796 [TBL] [Abstract][Full Text] [Related]
19. Low dose naltrexone for induction of remission in Crohn's disease. Segal D; Macdonald JK; Chande N Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033 [TBL] [Abstract][Full Text] [Related]
20. A real-life pediatric experience of Crohn's disease exclusion diet at disease onset and in refractory patients. Scarallo L; Banci E; De Blasi A; Paci M; Renzo S; Naldini S; Barp J; Pochesci S; Fioretti L; Pasquini B; Cavalieri D; Lionetti P J Pediatr Gastroenterol Nutr; 2024 Sep; 79(3):592-601. PubMed ID: 38962891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]